Key result
Ciprofol protects the heart against isoproterenol-induced myocardial infarction by reducing cardiac oxidative stress, the inflammatory response, and cardiomyocyte apoptosis via activation of the Sirt1/Nrf2 signaling pathway.
Why the study?
Propofol has shown cardioprotective effects in cardiovascular diseases, but whether the related novel intravenous anesthetic ciprofol exerts cardioprotective effects on myocardial infarction remained unclear.
Does ciprofol reduce myocardial injury, oxidative stress, and inflammation in an isoproterenol-induced myocardial infarction model?
Does ciprofol reduce myocardial injury, oxidative stress, and inflammation in an isoproterenol-induced myocardial infarction model?
Ciprofol protects the heart against isoproterenol-induced myocardial infarction by reducing oxidative stress, inflammation, and apoptosis via activation of the Sirt1/Nrf2 pathway in a preclinical model.
Answers are grounded in this paper and cite their sources.
Animal data on ciprofol in MI remain hypothesis-generating; leaves open clinical translation.
Background and Purpose: Ciprofol (HSK3486), a novel 2,6-disubstituted phenol derivative, is a new intravenous anesthetic compound with a similar chemical structure to propofol. Animal studies have also shown that propofol plays a protective role in a variety of cardiovascular diseases, including myocardial infarction, myocardial ischemia-reperfusion injury and takotsubo syndrome. However, whether ciprofol exerts cardioprotective effects on myocardial infarction remains unclear. Thus, the aim of this work was to explore the potential cardioprotective mechanism of ciprofol on isoproterenol (ISO)-induced myocardial infarction. Experimental Approach: In the present study, male C57BL/6 mice were subjected to subcutaneous injection of ISO (100 mg/kg) for 2 consecutive days to induce experimental myocardial infarction. Herein, we found that ciprofol could inhibit the abnormal increase in myocardial injury enzymes, the area of myocardial infarction and cardiac dysfunction in ISO-treated mice. Ciprofol administration increased the activity of superoxide dismutase and reduced the levels of NADPH oxidase and malondialdehyde in ISO-treated hearts. Additionally, ciprofol administration markedly reduced the expression of pro-inflammatory cytokines and cardiomyocyte apoptosis. In an in vitro model, the results also confirmed that ciprofol could inhibit ISO-induced oxidative damage, the inflammatory response and cardiomyocyte apoptosis. Moreover, ciprofol can activate the sirtuin1 (Sirt1)/nuclear factor erythroid 2-related factor 2 (Nrf2) pathway and Sirt1 and Nrf2 inhibition almost abolished ciprofol-mediated cardioprotective effects. Interpretation: Ciprofol protects the heart against ISO-induced myocardial infarction by reducing cardiac oxidative stress, the inflammatory response and cardiomyocyte apoptosis.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2022) studied Isoproterenol-induced myocardial infarction (n=80). Ciprofol vs. Normal saline was evaluated on Myocardial injury (CK-MB, LDH, cTnT), infarct size, and cardiac function (p=<0.05). Ciprofol protects the heart against isoproterenol-induced myocardial infarction by reducing cardiac oxidative stress, the inflammatory response, and cardiomyocyte apoptosis via activation of the Sirt1/Nrf2 signaling pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: